Page 85 - 《中国药房》2024年1期
P. 85

碳青霉烯类耐药肺炎克雷伯菌致血流感染风险预测模型的构建
                                                                                                           Δ


                                               #
          于小杰 ,杨文明,宋萍萍,魏 颖,王 娜(秦皇岛市第一医院药学部,河北 秦皇岛 066000)
                *
          中图分类号  R969.3      文献标志码  A      文章编号  1001-0408(2024)01-0075-05
          DOI  10.6039/j.issn.1001-0408.2024.01.13


          摘  要  目的  构建碳青霉烯类耐药肺炎克雷伯菌(CRKP)致血流感染(BSI)风险预测模型。方法  回顾性分析秦皇岛市第一医
          院2019年1月-2022年6月253例肺炎克雷伯菌致BSI患者的临床资料,将2019年1月-2021年12月收治的患者(223例)作为模
          型组,2022年1-6月收治的患者(30例)作为验证组。根据是否检出CRKP将模型组患者分为CRKP亚组(56例)和碳青霉烯类敏
          感肺炎克雷伯菌(CSKP)亚组(167例),对两亚组患者性别、年龄、合并基础疾病等基本信息进行单因素分析和多因素Logistic分
          析,筛选CRKP致BSI的独立危险因素并构建风险预测模型;以验证组患者为对象,对所建模型进行验证。结果  患者入住重症监
          护病房(ICU)、使用免疫抑制剂和经验性抗感染治疗中使用碳青霉烯类抗菌药物、抗革兰氏阳性球菌药物是CRKP致BSI的独立
          危险因素(比值比分别为 3.749、3.074、2.909、9.419,95% 置信区间分别为 1.639~8.572、1.292~7.312、1.180~7.717、2.877~
          30.840,P<0.05);所建风险预测模型的 P 值为 0.365,模型受试者工作特征曲线的曲线下面积(AUC)为 0.848(95% 置信区间为
          0.779~0.916,P<0.001),分值临界值为6.5。用于验证组患者时,模型预测的总体准确率为86.67%,其生存曲线的AUC为0.926
         (95%置信区间为0.809~1.000,P<0.001)。结论  患者入住ICU、使用免疫抑制剂和经验性抗感染治疗中使用碳青霉烯类抗菌药
          物、抗革兰氏阳性球菌药物是CRKP致BSI的独立危险因素;基于上述因素所建的CRKP致BSI风险预测模型的预测准确性良好。
          关键词  碳青霉烯类耐药肺炎克雷伯菌;血流感染;危险因素;风险预测模型

          Construction  of  a  risk  prediction  model  for  bloodstream  infection  induced  by  carbapenem-resistant
          Klebsiella pneumoniae
          YU Xiaojie,YANG Wenming,SONG Pingping,WEI Ying,WANG Na(Dept.  of  Pharmacy,  First  Hospital  of
          Qinhuangdao, Hebei Qinhuangdao 066000, China)

          ABSTRACT   OBJECTIVE To construct a risk prediction model for bloodstream infection (BSI) induced by carbapenem-resistant
          Klebsiella  pneumoniae (CRKP).  METHODS  Retrospective  analysis  was  conducted  for  clinical  data  from  253  patients  with  BSI
          induced  by  K.  pneumoniae  in  the  First  Hospital  of  Qinhuangdao  from  January  2019  to  June  2022.  Patients  admitted  from  January
          2019 to December 2021 were selected as the model group (n=223), and patients admitted from January 2022 to June 2022 were
          selected  as  the  validation  group (n=30).  The  model  group  was  divided  into  the  CRKP  subgroup (n=56)  and  the  carbapenem-
          sensitive K. pneumoniae (CSKP) subgroup (n=167) based on whether CRKP was detected or not. The univariate and multivariate
          Logistic analyses were performed on basic information such as gender, age and comorbid underlying diseases in two subgroups of
          patients;  independent  risk  factors  were  screened  for  CRKP-induced  BSI,  and  a  risk  prediction  model  was  constructed.  The
          established  model  was  verified  with  patients  in  the  validation  group  as  the  target.  RESULTS  Admissioning  to  intensive  care  unit
         (ICU),  use  of  immunosuppressants,  empirical  use  of  carbapenems  and  empirical  use  of  antibiotics  against  Gram-positive  coccus
          were  independent  risk  factors  of  CRKP-induced  BSI (ORs  were  3.749,  3.074,  2.909,  9.419,  95%CIs  were  1.639-8.572,  1.292-
          7.312, 1.180-7.717, 2.877-30.840, P<0.05). Based on this, a risk prediction model was established with a P value of 0.365. The
          AUC  of  the  receiver  operating  characteristic (ROC)  curve  of  the  model  was  0.848  [95%CI (0.779,  0.916),  P<0.001],  and  the
          critical score was 6.5. In the validation group, the overall accuracy of the prediction under the model was 86.67%, and the AUC of
          ROC  curve  was  0.926  [95%CI (0.809,  1.000],  P<0.001].  CONCLUSIONS  Admission  to  ICU,  use  of  immunosuppressants,
          empirical  use  of  carbapenems  and  empirical  use  of  antibiotics  against  Gram-positive  coccus  are  independent  risk  factors  of  CRKP-
          induced BSI. The CRKP-induced BSI risk prediction model based on the above factors has good prediction accuracy.
          KEYWORDS    carbapenem-resistant Klebsiella pneumoniae; bloodstream infection; risk factors; risk prediction model



             Δ 基金项目 秦 皇 岛 市 科 学 技 术 研 究 与 发 展 计 划 项 目(No.        近年来,多重耐药肺炎克雷伯菌(multidrug-resistant
          202004A088,No.201902A210)                          Klebsiella pneumoniae,MDR-KP)的检出率逐年上升。
             *第一作者 主管药师,硕士。研究方向:临床药学。电话:0335-
                                                             碳青霉烯类抗菌药物是治疗碳青霉烯敏感 MDR-KP 感
          5908439。E-mail:yuxiaojie213@163.com
                                                             染的重要选择,但随着该类抗菌药物的广泛应用,碳青
             # 通信作者 主任药师,博士。研究方向:医院药学。电话:0335-
          5908456。E-mail:wangncqhd@163.com                   霉烯类耐药肺炎克雷伯菌(carbapenem-resistant K. pneu‐


          中国药房  2024年第35卷第1期                                                  China Pharmacy  2024 Vol. 35  No. 1    · 75 ·
   80   81   82   83   84   85   86   87   88   89   90